A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Progesterone (Crinone)

Progesterone class · 8 generic manufacturers · 17 ANDAs filed at FDA.

First FDA approval1978-05-11
Generic availableYes · 8 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$11,832 in CY2024 Part D spend327 claims · 170 beneficiaries · 329 plans surveyed

Lowest NADAC
$0.211/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.98
Across all dosage forms in distribution.
Highest NADAC
$14.87
Wide spread — brand-strength NDCs still in market.
Plans with PA
19 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Progesterone used for?

Progesterone is a Progesterone medication tracked in Medicare Part D.

Is there a generic for Progesterone?

Yes. 17 ANDAs filed at FDA, 8 generic manufacturers currently shipping.

How much does my plan pay for Progesterone?

Across 329 Part D plans, Progesterone averages $1.98/unit (NADAC). Lowest available: $0.211/unit. Highest in distribution: $14.87/unit.

Is Progesterone on the FDA shortage list?

No. Progesterone is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.